Current stock page

Stock Analysis

UroGen Pharma Ltd. (URGN) Stock Analysis

UroGen Pharma Ltd. (URGN) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

URGN Stock Analysis Summary

UroGen Pharma Ltd. (URGN) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 68/100. Risk is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

URGN at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$26.18
AIQ Score53/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$1.32B
P/E Ratio (TTM)-19.83
Forward P/E—
EPS (Q3 FY2026)-$0.03
Revenue (Q3 FY2026)$89M
Dividend Yield (TTM)0.00%
Beta1.33
Volume700.02K
52-week range$16.50-$50.81
RSI 1428.74
50-Day SMA$37.00
200-Day SMA$31.69
Analyst Price Target$58.00
Next EarningsMar 1, 2027
As of Nov 13, 2026 · Market close

URGNUroGen Pharma Ltd.

Healthcare / Biotechnology

Low Priority

In Line With Peers

NeutralEdge 5/10
$26.18−$0.21 (−0.80%)

Latest quote

  • Momentum
    40
  • Value
    64
  • Quality
    68
  • Risk resilience
    40
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

URGN Stock Analysis Summary

UroGen Pharma Ltd. (URGN) currently has an AIQ Score of 53/100, indicating a neutral setup. Quality is the strongest factor at 68/100. Risk resilience is the weakest current factor at 40/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, URGN has AIQ Score of 53/100 with Quality base of 68/100 and fading Risk resilience at 40/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (68/100) leads while Risk resilience (40/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.80% stock move · URGN classified in Biotechnology.

Current Evidence

NeutralURGN is in a neutral AIQ regime; Quality is the strongest visible factor at 68/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is URGN Bullish or Bearish Right Now?

URGN currently has a neutral overall setup. Quality is the strongest factor at 68/100, while Momentum is weakest at 40/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 68/100.
  • - Analyst target implies +121.54% upside from the latest quote.
Bear Case
  • - Momentum is weak at 40/100.
  • - Risk Resilience is weak at 40/100.
  • - Price is -17.38% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (36 vs 6).

Current Consensus

URGN's Technical Analysis Consensus is currently Strong Sell, with 6 buy, 4 neutral, and 36 sell votes. URGN's 14-day RSI is 28.74, which places the stock in an oversold momentum range. URGN's beta is 1.33, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in URGN?

The largest recent change in URGN is Momentum moving down by 12.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.

AIQ Score
-4.0
Momentum
-12.0
Quality
+1.0
Risk
-1.0

What Would Change the URGN Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

URGN Decision Framework

Public evidence layers, setup checks, and risk context for UroGen Pharma Ltd..

UroGen Pharma Ltd. (URGN) Stock Analysis

UroGen Pharma Ltd. has an AIQ Score of 53/100 in a Neutral regime. Quality is strongest at 68/100. Beta is 1.33, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextURGN is in a Neutral AIQ regime with score 53/100.
Signal ConflictThe primary conflict is that quality leads at 68/100 while momentum lags at 40/100.
Factor EvidenceMomentum 40/100 · Value 64/100 · Quality 68/100 · Risk 40/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 68/100.

TimingFail

Momentum is 40/100 and RSI (14) is 28.7.

Regime fitWait

URGN is in a Neutral regime at 53/100.

Risk controlFail

Risk factor is 40/100 with beta 1.33 and annual volatility 61.94%.

ConflictWait

Current conflict: quality leads at 68/100 while momentum lags at 40/100.

AIQ Score
53/100
Price
$26.18
Beta
1.33
RSI (14)
28.7

URGN Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

URGN Fundamentals

URGN valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$89M
Net income
-$1.46M
Free cash flow
-$15.27M
View full URGN fundamental analysis

URGN Technical Analysis

URGN technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
28.74
Price vs SMA-50
-29.25%
View full URGN technical analysis

URGN Stock Catalysts

Track URGN earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Mar 1, 2027
Analyst target
$58.00
News items
4
View URGN earnings and stock catalysts

URGN Dividend Analysis

URGN dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View URGN dividend history and analysis

URGN Financial Data

URGN revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$89M
EPS
-$0.03
Periods
8
View URGN financials

URGN Risk Analysis

URGN volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.33
Risk score
40/100
1Y volatility
61.94%
View URGN risk analysis

URGN Stock News

URGN stock news, market tone, recent headlines, and catalyst context.

News items
4
Updated
Nov 15, 2026
Sentiment
—
Read URGN stock news

URGN vs Biotechnology Peers

Current peer cohort: URGN · UTHR · VCEL · VKTX · VOR. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
URGN
Current stock
53/10064/10040/10040/1000.3961.94%Current
UTHR
United Therapeutics Corporation
76/10078/10068/10083/1000.7635.02%URGN vs UTHR
VCEL
Vericel Corporation
77/10065/10090/10064/1000.9345.04%URGN vs VCEL
VKTX
Viking Therapeutics, Inc.
41/100—47/10041/100-0.1569.18%URGN vs VKTX
VOR
Vor Biopharma Inc.
66/100—72/10046/1001.1593.53%URGN vs VOR
Pairwise Compare links: UTHR · VCEL · VKTX · VORURGN vs UTHRURGN vs VCELURGN vs VKTXURGN vs VORCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a URGN stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for URGN: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-19.83
As of Nov 13, 2026
Revenue growth
223.85%
Gross margin
91.41%
Current debt / equity
-1.57
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$89M
Quarter net income
-$1.46M
Quarter free cash flow
-$15.27M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Mixed
Momentum
Bearish
RSI 14
28.74
MACD
-3.37

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
40/100
Beta
1.33
Annual volatility
61.94%
Max drawdown
-50.79%

URGN Stock FAQ

What is URGN stock price today?

UroGen Pharma Ltd.'s current stock price is $26.18. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is URGN bullish or bearish right now?

URGN's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is URGN's market cap?

URGN's market cap is $1.32B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is URGN's current P/E ratio?

URGN's current P/E ratio is -19.83 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is URGN's RSI?

URGN's 14-day RSI is 28.74 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is URGN above its 50-day and 200-day moving averages?

URGN is -29.25% from its 50-day SMA and -17.38% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is URGN's next earnings date?

URGN's next earnings date is currently listed as Mar 1, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does URGN pay a dividend?

URGN's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.